MicroRNA-378-5p suppresses cell proliferation and induces apoptosis in colorectal cancer cells by targeting BRAF

Cancer Cell International

Ren Zhao²  Xianze Chen²  Haoxuan Wu²  Hanxing Sun²  Haoji Gao²  Xiaojian Zhang²  Tao Zhang²  Yang Deng²  Xiaopin Ji²  Bin Ma¹  Zhenlei Wang² 

[1] Department of Spine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, P R China;Department of General Surgery, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui Jin Er Road, Shanghai 200025, P R China

关键词: Apoptosis;    Proliferation;    BRAF;    miR-378-5p;    Colorectal cancer;   

Others  :  1217783
DOI  :  10.1186/s12935-015-0192-2

 received in 2014-12-01, accepted in 2015-03-30,  发布年份 2015

【 摘 要 】

MicroRNAs (miRNAs) are a group of small non-coding RNA molecules that potentially play a critical role in tumorigenesis. Increasing evidences indicate that miR-378-5p is dysregulated in numerous human cancers including colorectal cancer (CRC) which hypothesizes that miR-378-5p may play an important role in tumorigenesis. However, its role in CRC carcinogenesis remains poorly defined because of lacking target genes information. In the present study, it was demonstrated that the expression of miR-378-5p was down-regulated in CRC tissues and cell lines as determined by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Furthermore, overexpression of miR-378-5p suppressed cell proliferation, as indicated by CCK-8 assay. Flow cytometric analysis demonstrated that overexpression of miR-378-5p induced cell cycle arrest and promoted apoptosis in CRC cells. A luciferase reporter assay indicated that BRAF was a direct target of miR-378-5p. Western blot and qRT-PCR analysis indicated that BRAF was significantly down-regulated by miR-378-5p in CRC cells. Moreover, miR-378-5p was negatively associated with BRAF in CRC tissues compared to adjacent non-tumor tissues. These results demonstrate that down-regulation of miR-378-5p promotes CRC cells growth by targeting BRAF and restoration of their levels is a potentially promising therapeutic in CRC.

【 授权许可】

   
2015 Wang et al.; licensee BIoMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med. 2005; 352(5):476-87.
• [2]Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97.
• [3]He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004; 5(7):522-31.
• [4]Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006; 6(4):259-69.
• [5]Cho WC. OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer. 2007; 6:60. BioMed Central Full Text
• [6]Manikandan J, Aarthi JJ, Kumar SD, Pushparaj PN. Oncomirs: the potential role of non-coding microRNAs in understanding cancer. Bioinformation. 2008; 2(8):330-4.
• [7]Visone R, Croce CM. MiRNAs and cancer. Am J Pathol. 2009; 174(4):1131-8.
• [8]Wu WK, Lee CW, Cho CH, Fan D, Wu K, Yu J et al.. MicroRNA dysregulation in gastric cancer: a new player enters the game. Oncogene. 2010; 29(43):5761-71.
• [9]Eichner LJ, Perry MC, Dufour CR, Bertos N, Park M, St-Pierre J et al.. miR-378(*) mediates metabolic shift in breast cancer cells via the PGC-1beta/ERRgamma transcriptional pathway. Cell Metab. 2010; 12(4):352-61.
• [10]Lee DY, Deng Z, Wang CH, Yang BB. MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc Natl Acad Sci U S A. 2007; 104(51):20350-5.
• [11]Chen LT, Xu SD, Xu H, Zhang JF, Ning JF, Wang SF. MicroRNA-378 is associated with non-small cell lung cancer brain metastasis by promoting cell migration, invasion and tumor angiogenesis. Med Oncol. 2012; 29(3):1673-80.
• [12]Deng H, Guo Y, Song H, Xiao B, Sun W, Liu Z et al.. MicroRNA-195 and microRNA-378 mediate tumor growth suppression by epigenetical regulation in gastric cancer. Gene. 2013; 518(2):351-9.
• [13]Scapoli L, Palmieri A, Lo Muzio L, Pezzetti F, Rubini C, Girardi A et al.. MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression. Int J Immunopathol Pharmacol. 2010; 23(4):1229-34.
• [14]Li LH, Gao Q, Wang XY, Guo ZJ. miR-378 suppresses HBV-related hepatocellular carcinoma tumor growth by directly targeting the insulin-like growth factor 1 receptor. Zhonghua Gan Zang Bing Za Zhi. 2013; 21(8):609-13.
• [15]Callari M, Dugo M, Musella V, Marchesi E, Chiorino G, Grand MM et al.. Comparison of microarray platforms for measuring differential microRNA expression in paired normal/cancer colon tissues. PLoS One. 2012; 7(9): Article ID e45105
• [16]Mosakhani N, Sarhadi VK, Borze I, Karjalainen-Lindsberg ML, Sundstrom J, Ristamaki R et al.. MicroRNA profiling differentiates colorectal cancer according to KRAS status. Genes Chromosomes Cancer. 2012; 51(1):1-9.
• [17]Faltejskova P, Svoboda M, Srutova K, Mlcochova J, Besse A, Nekvindova J et al.. Identification and functional screening of microRNAs highly deregulated in colorectal cancer. J Cell Mol Med. 2012; 16(11):2655-66.
• [18]Wang YX, Zhang XY, Zhang BF, Yang CQ, Chen XM, Gao HJ. Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis. J Dig Dis. 2010; 11(1):50-4.
• [19]Helwak A, Kudla G, Dudnakova T, Tollervey D. Mapping the human miRNA interactome by CLASH reveals frequent noncanonical binding. Cell. 2013; 153(3):654-65.
• [20]Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell. 2008; 132(3):363-74.
• [21]Ciuffreda L, Del Bufalo D, Desideri M, Di Sanza C, Stoppacciaro A, Ricciardi MR et al.. Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Neoplasia. 2009; 11(8):720-31.
• [22]Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer. 2006; 94(6):776-80.
• [23]Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120(1):15-20.
• [24]Espinosa-Parrilla Y, Munoz X, Bonet C, Garcia N, Vencesla A, Yiannakouris N et al.. Genetic association of gastric cancer with miRNA clusters including the cancer-related genes MIR29, MIR25, MIR93 and MIR106: results from the EPIC-EURGAST study. Int J Cancer. 2014; 135(9):2065-76.
• [25]Huang J, Wu J, Li Y, Li X, Yang T, Yang Q et al.. Deregulation of serum MicroRNA expression is associated with cigarette smoking and lung cancer. BioMed Res Int. 2014; 2014:364316.
• [26]Cristobal I, Rincon R, Manso R, Carames C, Aguilera O, Madoz-Gurpide J et al.. Deregulation of miR-200b, miR-200c and miR-429 indicates its potential relevant role in patients with colorectal cancer liver metastasis. J Surg Oncol. 2014; 110(4):484-5.
• [27]Michael MZ SMOC, van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res. 2003; 1(12):882-91.
• [28]Chen MB, Wei MX, Han JY, Wu XY, Li C, Wang J et al.. MicroRNA-451 regulates AMPK/mTORC1 signaling and fascin1 expression in HT-29 colorectal cancer. Cell Signal. 2014; 26(1):102-9.
• [29]Kim NH, Cha YH, Kang SE, Lee Y, Lee I, Cha SY et al.. P53 regulates nuclear GSK-3 levels through miR-34-mediated Axin2 suppression in colorectal cancer cells. Cell Cycle. 2013; 12(10):1578-87.
• [30]Nagel R, le Sage C, Diosdado B, van der Waal M, Oude Vrielink JA, Bolijn A et al.. Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res. 2008; 68(14):5795-802.
• [31]Guo J, Miao Y, Xiao B, Huan R, Jiang Z, Meng D et al.. Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J Gastroenterol Hepatol. 2009; 24(4):652-7.
• [32]Zhang GJ, Zhou H, Xiao HX, Li Y, Zhou T. MiR-378 is an independent prognostic factor and inhibits cell growth and invasion in colorectal cancer. BMC Cancer. 2014; 14:109. BioMed Central Full Text
• [33]Redova M, Poprach A, Nekvindova J, Iliev R, Radova L, Lakomy R et al.. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med. 2012; 10:55. BioMed Central Full Text
• [34]Mikami M, Nosho K, Yamamoto H, Takahashi T, Maehata T, Taniguchi H et al.. Mutational analysis of beta-catenin and the RAS-RAF signalling pathway in early flat-type colorectal tumours. Eur J Cancer. 2006; 42(17):3065-72.
• [35]Matsukuma S, Yoshihara M, Kasai F, Kato A, Yoshida A, Akaike M et al.. Rapid and simple detection of hot spot point mutations of epidermal growth factor receptor, BRAF, and NRAS in cancers using the loop-hybrid mobility shift assay. J Mol Diagn. 2006; 8(4):504-12.
• [36]Rodriguez-Viciana P, Tetsu O, Oda K, Okada J, Rauen K, McCormick F. Cancer targets in the Ras pathway. Cold Spring Harb Symp Quant Biol. 2005; 70:461-7.
• [37]Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al.. Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892):949-54.
• [38]Santini D, Spoto C, Loupakis F, Vincenzi B, Silvestris N, Cremolini C et al.. High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice. Ann Oncol. 2010; 21(7):1565.
• [39]Troiani T, Zappavigna S, Martinelli E, Addeo SR, Stiuso P, Ciardiello F et al.. Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. Expert Opin Biol Ther. 2013; 13(2):241-55.
• [40]Troiani T, Vecchione L, Martinelli E, Capasso A, Costantino S, Ciuffreda LP et al.. Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. Br J Cancer. 2012; 106(10):1648-59.
• [41]Nosho K, Igarashi H, Nojima M, Ito M, Maruyama R, Yoshii S et al.. Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway. Carcinogenesis. 2014; 35(4):776-83.
• [42]Liu SM, Lu J, Lee HC, Chung FH, Ma N. miR-524-5p suppresses the growth of oncogenic BRAF melanoma by targeting BRAF and ERK2. Oncotarget. 2014; 5(19):9444-59.
• [43]Pagliuca A, Valvo C, Fabrizi E, di Martino S, Biffoni M, Runci D et al.. Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. Oncogene. 2013; 32(40):4806-13.
• [44]Wu GG, Li WH, He WG, Jiang N, Zhang GX, Chen W et al.. Mir-184 post-transcriptionally regulates SOX7 expression and promotes cell proliferation in human hepatocellular carcinoma. PLoS One. 2014; 9(2): Article ID e88796
• [45]Ma Y, She XG, Ming YZ, Wan QQ. miR-24 promotes the proliferation and invasion of HCC cells by targeting SOX7. Tumour Biol. 2014.
• [46]Shen F, Cai WS, Feng Z, Li JL, Chen JW, Cao J, et al. MiR-492 contributes to cell proliferation and cell cycle of human breast cancer cells by suppressing SOX7 expression. Tumour Biol. 2014.